Moderna initial Phase 1/2 data for mRNA-2808 in relapsed/refractory multiple myeloma: manageable safety
Moderna reports initial Phase 1/2 data for mRNA-2808 in relapsed/refractory multiple myeloma showing responses with manageable safety
- Trial enrolled heavily pretreated relapsed/refractory multiple myeloma patients, with 11 patients evaluable for efficacy in Phase 1/2.
- Moderna reported 4 responses among the 11 evaluable patients treated with multiplexed mRNA therapeutic mRNA-2808.
- Initial mRNA-2808 data were selected for oral presentation at the 2026 ASH Annual Meeting.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.